12-Months treatment of men with androgenetic alopecia with finasteride: Multicentre Polish study;Wyniki 12-miesiȩcznego leczenia finasterydem mȩżczyzn z łysieniem androgenowym: Wieloośrodkowe badanie Polskie

Przeglad Dermatologiczny

Volumn 89, Issue 5, 2002, Pages 377-380

  Broniarczyk Dyła, Grazyna ^a   Prusińska Bratoś, Magdalena ^a   Dubla Berner, Małgorzata ^a   Langner, Andrzej ^b   Placek, Waldemar ^c  

^a Kat Klin Dermatol Wenerologii AM   (Poland)

^b Klinika Dermatologiczna Medical University of Warsaw   (Poland)

^c Kat/Klin Dermatol/Wenerol AM   (Poland)

Author keywords

5 reductase; Androgenetic alopecia; Finasteride

Indexed keywords

FINASTERIDE; STEROID 5ALPHA REDUCTASE;

ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; HAIR GROWTH; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE TYPE ALOPECIA; MULTICENTER STUDY; PATHOGENESIS; POLAND; SEXUAL FUNCTION; TREATMENT OUTCOME;

EID: 0036447143     PISSN: 00332526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Passchier J.: Quality of life issues in male pattern hair loss. Dermatology 1998, 197, 217-218.
2. Broniarczyk-Dyla G., Prusińska-Bratoś M., Arkuszewska C.: Etiopatogeneza, obraz kliniczny i metody leczenia łysienia androgenowego. Dermatologia Estetyczna 2000, 2, 4-9.
3. Waldstreicher J., Fiedler V., Hordinsky M. i inni: Effects of finasteride on dihydrotestosterone content of scalp skin in men with male patern baldness. J Invest Dermatol 1994, 102, 615.
4. Bergfeld W.F.: Androgenic alopecia an autosomal dominant disorder. Am J Med 1995, 98 supl., 1A, 95-98.
5. Hoffman R., Happle R.: Current understanding of androgenetic alopecia. Part I: Etiopathogenesis. Eur J Dermatol 2000, 10, 319-326.
6. Kauffman K.D.: Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol Clin 1996, 14, 697-711.
7. Hoffman R., Happle R.: Die pathogenetische bedeutung der 5α-reductase-isoenzyme fur die androgenerische alopezie. Hautarzt 1999, 50, 165-173.
8. Moore R.J., Wilson J.D.: Steroid 5α-reductase activity in cultured human fibroblasts: Biochemical and genetic evidence for two distinct enzyme activities. J Biol Chem 1974, 251, 5895-5900.
9. McConnell J.D., Wilson J.D., George F.W. i inni: Finasteride, an inhibitor of 5 α-reductase, supresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992, 74, 505-508.
10. Cather J.C., Lane D., Heaphy M.R. Jr i inni: Finasteride-an update and review. Cutis 1999, 64, 167-172.
11. Kaufman K.D., Olsen E.A., Whiting D. i inni: Finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Am Acad Dermatol 1998, 39, 578-589.
12. Kaufman K.D.: Treatment of men with androgenetic alopecia with finasteride: The 2-year experience. Clin Dermatol 2000, Singapore-Programme and Book of Abstracts, 1998, 103.
13. Chen W., Zouboulis C.S., Orfanos C.E.: The 5α-reductase spectrum and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 1996, 193, 177-184.
14. Kaufman K.D., De Villez R., Roberts J. i inni: A 12 month pilot clinical study of the effects of finasteride on men with male pattern baldness. J Invest Dermatol 1994, 102, 615.
15. Leyden J., Dunlap F., Miller B. i inni: Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999, 40, 930-937.
16. Overstreet J.W., Fuh V.L., Gould J. i inni: Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol 1999, 162, 1295-1300.
17. Hamilton J.B.: Patterned hair loss in man; types and incidences. Ann NY Acad Sci 1951, 53, 708-728.
18. Kaufman K.D.: Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 2002, 12, 38-49.